Skip to main content
Premium Trial:

Request an Annual Quote

Products & Services: Dec 10, 2009

Premium

Bioo Scientific has introduced the T3 Conjugation Kit for targeted in vivo delivery of siRNAs or other RNAi agents.

The T3 technology involves a carrier to an antibody that is specific to a receptor or other extracellular domain specific to the targeted cell or tissue type. The conjugate can then be loaded with an RNAi molecule.

According to the company, the kit can also be used for the in vitro delivery of siRNAs in primary cells or cell lines with mixed populations.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.